Accordingly, based on our previous data indicating a high expression of GRP78 in mesothelioma REN and MM98 cells [19], we investigated the mechanism of action of the clinical-stage drug BOLD-100 on MPM cells, to disclose the potential of an innovative drug that could be combined with the standard-of-care drugs in the clinic for the treatment of MPM. The gene discussed is HSPA5; the disease is mesothelioma.